VIGAMOX Drug Patent Profile

When do Vigamox patents expire, and when can generic versions of Vigamox launch?

Vigamox is a drug marketed by Harrow Eye and is included in one NDA.

The generic ingredient in VIGAMOX is moxifloxacin hydrochloride. There are eighteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the moxifloxacin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vigamox

A generic version of VIGAMOX was approved as moxifloxacin hydrochloride by TEVA PHARMS USA on February 18^th, 2014.

Summary for VIGAMOX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	105
Clinical Trials:	34
Patent Applications:	2,242
Drug Prices:	Drug price information for VIGAMOX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIGAMOX
What excipients (inactive ingredients) are in VIGAMOX?	VIGAMOX excipients list
DailyMed Link:	VIGAMOX at DailyMed

See drug prices for VIGAMOX

See drug sales revenues for VIGAMOX

Recent Clinical Trials for VIGAMOX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tanta University	EARLY_PHASE1
Kafrelsheikh University	Phase 4
Benha University	Phase 1

See all VIGAMOX clinical trials

Pharmacology for VIGAMOX

Drug Class

Fluoroquinolone Antibacterial

Paragraph IV (Patent) Challenges for VIGAMOX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIGAMOX	Ophthalmic Solution/Drops	moxifloxacin hydrochloride	0.5%	021598	1	2005-12-22

US Patents and Regulatory Information for VIGAMOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harrow Eye	VIGAMOX	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	021598-001	Apr 15, 2003	AT1	RX	Yes	Yes

Expired US Patents for VIGAMOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Harrow Eye	VIGAMOX	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	021598-001	Apr 15, 2003
Harrow Eye	VIGAMOX	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	021598-001	Apr 15, 2003
Harrow Eye	VIGAMOX	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	021598-001	Apr 15, 2003

International Patents for VIGAMOX

See the table below for patents covering VIGAMOX around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	211472
Spain	2519190
Cyprus	2111	7-(1-Pyrrolidinyl)-3-quinolone- and -naphthyridone-carboxylic-acid derivatives metho for their preparation and for substituted mono- and bi-cyclic pyrrolidine intermediates and their antibacterial

Supplementary Protection Certificates for VIGAMOX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0350733	300111	Netherlands
0350733	11/2000	Austria		PRODUCT NAME: MOXIFLOXACIN, DESSEN PHARMAZEUTISCH VERWENDBARE HYDRATE UND SAEUREADDITIONSSALZE, DESSEN ALKALI-ERDALKALI-SILBER- UND GUANIDINIUMSALZE, SOWIE DESSEN C1 - C4 ALKYL- ODER; NAT. REGISTRATION NO/DATE: 1-23494, 1-23495, 1-23496 20000215; FIRST REGISTRATION: DE 45263.00.00 19990621
0780390	PA2004012,C0780390	Lithuania		PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-1,4-DIHIDRO-8-METOKSI-7-((4AS, 7AS)-OKTAHIDRO-6H-PIROLO(3,4-B)PIRIDIN-6-IL)-4-OKSO-3-CHINOLINKARBOKSIRUGSTIES HIDROCHLORIDAS); REGISTRATION NO/DATE: 04/8383/3 20040309

VIGAMOX Market Analysis and Financial Projection

Last updated: February 11, 2026

What Are the Market Dynamics for VIGAMOX?

VIGAMOX (moxifloxacin ophthalmic solution) is used to treat bacterial conjunctivitis and other eye infections. Sales have been driven by its broad-spectrum activity, prescription frequency, and the prevalence of eye infections.

Market Size and Growth Drivers

• The global ophthalmic drugs market was valued at approximately $49 billion in 2022, with infectious disease treatments accounting for 15–20%.
• Eye infection incidences, including bacterial conjunctivitis, affect an estimated 1.8 million Americans annually (American Academy of Ophthalmology).
• VIGAMOX holds a significant share, especially in the United States, competing with antibiotics like besifloxacin and ofloxacin.
• The drug’s market penetration benefits from prescriptions in adult populations, especially with increased awareness and diagnosis.

Competitive Landscape

• VIGAMOX’s main competitors are other fluoroquinolone eye drops. It faces competition from off-label uses of oral antibiotics but maintains dominance in topical formulations.
• Patent exclusivity expired in August 2023, opening potential for generic entrants.
• Industry shifts include increased surveillance for antibiotic resistance, affecting prescribing habits.

Regulatory and Patent Status

• VIGAMOX received FDA approval in 2003.
• It was protected by patents until August 2023, after which generic versions entered the market.

How Does VIGAMOX’s Financial Trajectory Look?

Revenue Trends

• Pre-2023: Peak global sales reached approximately $250 million annually, driven by U.S. prescriptions and limited generics.
• Post-patent expiry: Market share decline expected; generic competition weighed on revenue.

Profitability

• The drug was highly profitable with margins exceeding 40% during patent protection.
• Costs of manufacturing are relatively low due to established production processes.
• Revenue erosion expected in 2024-2025 due to price competition.

Market Projections

Year	Estimated Revenue (USD millions)	Key Factors
2023	240–250	Before patent expiry
2024	120–150	Entry of generics, price competition
2025	80–100	Continued generic penetration

Impact of Generic Entry

• Price reductions of 60–80% observed in similar ophthalmic drugs post-generic entry.
• Sales volume could increase in some markets as affordability improves, but overall revenue declines.

What Are the Future Market and Financial Risks?

• Patent Litigation and Patent Strategies: Patent litigation or new patent filings may influence the timing of generic entry.
• Antibiotic Stewardship: Growing emphasis on antibiotic resistance may lower prescription volumes.
• Regulatory Changes: New guidelines or restrictions on antibiotic use could further diminish sales.
• Market Penetration: Developments in branded or combination therapies could impact VIGAMOX’s market share.

How Do Market Trends Affect VIGAMOX?

• Rise in generic competition reduces revenues.
• Increasing use of preservative-free formulations poses a threat to VIGAMOX, which contains benzalkonium chloride.
• New formulations or delivery methods could regain some market share.

Key Takeaways

• VIGAMOX was a leading ophthalmic antibiotic with peak sales of around $250 million before patent expiry.
• The expiration in August 2023 led to the entry of generics, with revenues expected to decline substantially.
• Competitive pressures, antibiotic stewardship policies, and potential formulation innovations influence its future market position.
• Industry growth is tied to the prevalence of bacterial eye infections, which remain common globally.
• Financial margins diminished post-generic entry, reflecting typical trends in branded pharmaceuticals.

FAQs

1. How quickly did generic versions of VIGAMOX enter the market after patent expiry?
Within weeks of patent expiration in August 2023, multiple generics launched, leading to immediate price reductions.

2. What is the primary driver for sales in the ophthalmic antibiotic market?
The number of bacterial eye infection cases combined with physician prescribing habits.

3. How susceptible is VIGAMOX to market threats from resistance?
Resistance development has been reported in fluoroquinolones, which may reduce efficacy and prescribing.

4. Are there any notable regulatory developments affecting VIGAMOX?
No recent approvals or restrictions; however, stewardship initiatives may influence prescribing behavior.

5. What strategies could maintain profitability post-generic entry?
Differentiation through formulation improvements, expanding indications, or licensing alternative delivery systems.

---

[1] IQVIA, Global Ophthalmic Drugs Market Report, 2022
[2] American Academy of Ophthalmology, Eye Infection Statistics, 2022
[3] U.S. Food and Drug Administration, Drug Patent and Exclusivity Data, 2023